Life Science Technical Accounting CPE Update 2024 (ONLINE EVENT: September 17-18, 2024)

From Gross to Net Estimates to IPR&D and intangible assets to Revenue Recognition examples, M&A Trends, Complex Debt and Equity Structures in Life Sciences, Tax News, ESG, Regulatory Updates, Joint Ventures: Accounting Considerations and latest updates, this conference will address the latest developments in key areas. You’ll hear from experts at Deloitte, Ernst & Young, Effectus Group, life science analysts, and your industry counterparts.

LEARNING OBJECTIVES:

• Understand the latest accounting changes in key areas
• Recognize the timelines and key factors affecting the life science industry
• Begin to assess the effects of these standards on your company or clients

Secure your place: https://bit.ly/4cF5RnD

Agenda

Agenda: DAY 1

8:45 - 10:05 - Accounting for R&D and Clinical Trials

• R&D Funding Arrangements
• R&D Cost Classifications
• Other Intangible Assets
• SEC Comment Letter Trends

10:05 - 10:30 - Break

10:30 - 11:30 - Tax Update

• Latest legislative developments
• Key Tax Proposals
• Build Back Better Act Observations
• Possible timing and other legislative priorities

11:30 - 12:15 - Lunch Break

12:15 - 1:35 - Revenue Recognition: ASC 606 Practical Issues - Life Sciences

• Scope of Contract
• Performance Obligations
• Nature of promise: sales of points
• Collaboration agreements
• Sales using third-party platforms
• Gross vs Net
• Counterparty Perspective

1:35 - 1:50 - Break

1:50 - 3:05 - M&A in Life Sciences

• Industry Trends
• Accounting Considerations

3:10 - 4:40 - IPR&D and Intangible Assets

• Accounting Insights

Agenda: DAY 2

8:45 - 10:15 - Convertible Debt

• Accounting Considerations
• When should companies consider convertible debt?
• Convertible structure in the life science financing cycle
• Changes of control, tax implications, size, maturity, and other questions

10:15 - 10:30 - Break

10:30 - 12:00 - Joint Ventures, Consolidations and VIEs: Accounting Considerations

• Consolidation of controlled subsidiaries
• Equity method investments
• Financial assets

12:00 - 12:30 - Lunch Break

12:30 - 1:40 - ESG

• ESG Landscape: Regulatory Developments
• Operationalizing ESG & Sustainability
• Disclosure Trends in Life Sciences Industry
• Taking Action

1:40 - 1:45 - Break

1:45 - 3:15 - Regulatory Update

• Update on SEC Proposed Rule: Cybersecurity Risk Management, Strategy Governance and Incident Disclosure
• Market Trends
• SEC Requirements Explained
• ESG
• Adoption Timeline
• The Framework
• Disclosure Examples
• Financial Accounting Update
• FASB Project Update
• ASUs
• Issues on the horizon

3:15 - 3:25 - Break

3:25 - 4:45 - Gross to Net

• Introduction and Overview
• Industry View
• Estimation Methodology
• Approaching Launch
• Key Challenges
• SEC Comments
• Close and Financial Reporting
• GTN Hot Topics Discussion

Speakers

• Nathan Mitchell Deloitte, Partner
• Phil Howard Ernst & Young, Partner
• Andrew Lineback Ernst & Young, Senior Manager
• Nick Lubold Deloitte, Manager
• Jenna Tarapani Deloitte, Senior Manager
• Christie Hutchinson Effectus Group, Director
• Travis Combs Effectus Group, Managing Director
• Rochelle Tsui Ernst & Young, Manager
• Tim Geringer Ernst & Young, Senior Manager
• Aleks Zabreyko Connor Group, Managing Partner
• Jeffrey Kummer Deloitte, Director of Tax Policy
• Randa Ghantous Connor Group, Partner
• Kevin Dougherty Deloitte, Tax Partner
• Eli Seller Effectus Group, Managing Director, Technical Accounting & IPO